Journal Article
. 2010 Mar;120(3).
doi: 10.1007/s10549-010-0814-2.

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Michael Knauer 1 Stella Mook  Emiel J T Rutgers  Richard A Bender  Michael Hauptmann  Marc J van de Vijver  Rutger H T Koornstra  Jolien M Bueno-de-Mesquita  Sabine C Linn  Laura J van 't Veer  
Affiliations
  • PMID: 20204499
  •     64 citations

Abstract

Multigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value of the 70-gene MammaPrint signature for chemotherapy (CT) benefit in addition to endocrine therapy (ET) from pooled study series. For 541 patients who received either ET (n = 315) or ET + CT (n = 226), breast cancer-specific survival (BCSS) and distant disease-free survival (DDFS) at 5 years were assessed separately for the 70-gene high and low risk groups. The 70-gene signature classified 252 patients (47%) as low risk and 289 (53%) as high risk. Within the 70-gene low risk group, BCSS was 97% for the ET group and 99% for the ET + CT group at 5 years with a non-significant univariate hazard ratio (HR) of 0.58 (95% CI 0.07-4.98; P = 0.62). In the 70-gene high risk group, BCSS was 81% (ET group) and 94% (ET + CT group) at 5 years with a significant HR of 0.21 (95% CI 0.07-0.59; P < 0.01). DDFS was 93% (ET) versus 99% (ET + CT), respectively, in the 70-gene low risk group, HR 0.26 (95% CI 0.03-2.02; P = 0.20). In the high risk group DDFS was 76 versus 88%, HR of 0.35 (95% CI 0.17-0.71; P < 0.01). Results were similar in multivariate analysis, showing significant survival benefit by adding CT in the 70-gene high risk group. A significant and clinically meaningful benefit was observed by adding chemotherapy to endocrine treatment in 70-gene high risk patients. This benefit was not significant in low risk patients, who were at such low risk for recurrence and cancer-related death, that adding CT does not appear to be clinically meaningful.

Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden.
Amy Cyr, William E Gillanders, +3 authors, Julie A Margenthaler.
Ann Surg Oncol, 2010 Oct 01; 17 Suppl 3. PMID: 20853051    Free PMC article.
Breast cancer assessment tools and optimizing adjuvant therapy.
Catherine Oakman, Libero Santarpia, Angelo Di Leo.
Nat Rev Clin Oncol, 2010 Oct 27; 7(12). PMID: 20975745
Review.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
Review.
A signature of immune function genes associated with recurrence-free survival in breast cancer patients.
Maria Libera Ascierto, Maciej Kmieciak, +10 authors, Masoud H Manjili.
Breast Cancer Res Treat, 2011 Apr 12; 131(3). PMID: 21479927    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho.
Breast Cancer Res, 2011 Jul 27; 13(3). PMID: 21787441    Free PMC article.
Review.
SEOM clinical guidelines for using molecular markers in clinical practice.
Virginia Arrazubi, Roberto Pazo, Dolores Isla, José Luis Pérez Gracia.
Clin Transl Oncol, 2011 Aug 09; 13(8). PMID: 21821495
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Laura J Esserman, Donald A Berry, +32 authors, I-SPY 1 TRIAL Investigators.
Breast Cancer Res Treat, 2011 Dec 27; 132(3). PMID: 22198468    Free PMC article.
Highly Cited.
'Omic approaches to preventing or managing metastatic breast cancer.
Obi L Griffith, Joe W Gray.
Breast Cancer Res, 2012 Jan 06; 13(6). PMID: 22216753    Free PMC article.
Review.
Single sample expression-anchored mechanisms predict survival in head and neck cancer.
Xinan Yang, Kelly Regan, +6 authors, Yves A Lussier.
PLoS Comput Biol, 2012 Feb 01; 8(1). PMID: 22291585    Free PMC article.
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.
Shannon Puhalla, Saveri Bhattacharya, Nancy E Davidson.
Mol Oncol, 2012 Mar 13; 6(2). PMID: 22406404    Free PMC article.
Review.
Patients with positive axillary lymph nodes: how to use genomic assays.
Ruta Rao.
Curr Treat Options Oncol, 2012 Mar 20; 13(2). PMID: 22426945
The 70-Gene Signature as Prognostic Factor for Elderly Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer.
Steffi Hartmann, Bernd Gerber, +2 authors, Toralf Reimer.
Breast Care (Basel), 2012 May 04; 7(1). PMID: 22553468    Free PMC article.
Strategies for the discovery and development of therapies for metastatic breast cancer.
Bedrich L Eckhardt, Prudence A Francis, Belinda S Parker, Robin L Anderson.
Nat Rev Drug Discov, 2012 Jun 02; 11(6). PMID: 22653217
Highly Cited. Review.
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Masoud H Manjili, Kayvan Najarian, Xiang-Yang Wang.
Future Oncol, 2012 Jul 07; 8(6). PMID: 22764768    Free PMC article.
Review.
Accelerated partial breast irradiation for early-stage breast cancer: controversies and current indications for use.
Lisa C Klepczyk, Kimberly S Keene, Jennifer F De Los Santos.
Curr Treat Options Oncol, 2012 Nov 28; 14(1). PMID: 23179757
Review.
Gene signatures in breast cancer: current and future uses.
Enrique Espinosa Arranz, Juan Ángel Fresno Vara, Angelo Gámez-Pozo, Pilar Zamora.
Transl Oncol, 2013 Jan 17; 5(6). PMID: 23323153    Free PMC article.
Interpreting personal transcriptomes: personalized mechanism-scale profiling of RNA-seq data.
Alan Perez-Rathke, Haiquan Li, Yves A Lussier.
Pac Symp Biocomput, 2013 Feb 21;. PMID: 23424121    Free PMC article.
A prognosis classifier for breast cancer based on conserved gene regulation between mammary gland development and tumorigenesis: a multiscale statistical model.
Yingpu Tian, Baozhen Chen, +2 authors, Zhongxian Lu.
PLoS One, 2013 Apr 09; 8(4). PMID: 23565194    Free PMC article.
Identification and validation of a new set of five genes for prediction of risk in early breast cancer.
Giorgio Mustacchi, Maria Pia Sormani, +5 authors, Luca Morandi.
Int J Mol Sci, 2013 May 08; 14(5). PMID: 23648477    Free PMC article.
Breast cancer metastasis: issues for the personalization of its prevention and treatment.
Natascia Marino, Stephan Woditschka, +4 authors, Patricia S Steeg.
Am J Pathol, 2013 Jul 31; 183(4). PMID: 23895915    Free PMC article.
Review.
Profiling the immune stromal interface in breast cancer and its potential for clinical impact.
Sheeba Irshad, Anita Grigoriadis, +2 authors, Andrew Tutt.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904829    Free PMC article.
Molecular profiling for breast cancer: a comprehensive review.
Muaiad Kittaneh, Alberto J Montero, Stefan Glück.
Biomark Cancer, 2013 Nov 20; 5. PMID: 24250234    Free PMC article.
Review.
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.
Anna Tessari, Dario Palmieri, Serena Di Cosimo.
Pharmgenomics Pers Med, 2014 Jan 10; 7. PMID: 24403841    Free PMC article.
Review.
Breast Cancer Biomarkers: Utility in Clinical Practice.
Fanny Le Du, Naoto T Ueno, Ana M Gonzalez-Angulo.
Curr Breast Cancer Rep, 2014 Jan 15; 5(4). PMID: 24416469    Free PMC article.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
Kristin Jonsdottir, Jörg Assmus, +4 authors, Emiel A M Janssen.
PLoS One, 2014 Mar 07; 9(3). PMID: 24599057    Free PMC article.
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
P Sinn, S Aulmann, +6 authors, A Schneeweiss.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(9). PMID: 24771945    Free PMC article.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.
Umar Wazir, Kefah Mokbel.
World J Clin Oncol, 2014 Dec 11; 5(5). PMID: 25493218    Free PMC article.
Multigene prognostic tests in breast cancer: past, present, future.
Balázs Győrffy, Christos Hatzis, +3 authors, Lajos Pusztai.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848861    Free PMC article.
Highly Cited. Review.
The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy.
François Bertucci, Pascal Finetti, Daniel Birnbaum.
Breast Cancer Res, 2015 Apr 19; 17. PMID: 25887620    Free PMC article.
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.
Hideo Shimizu, Yoshiya Horimoto, +14 authors, Mitsue Saito.
Breast Care (Basel), 2015 Jul 22; 10(2). PMID: 26195940    Free PMC article.
Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.
Eun Sook Ko, Heon Han, +5 authors, Seok Jin Nam.
Korean J Radiol, 2015 Sep 12; 16(5). PMID: 26357493    Free PMC article.
Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.
A Kuijer, A C M van Bommel, +7 authors, Th van Dalen.
Genet Med, 2015 Nov 20; 18(7). PMID: 26583684
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients.
Meng Zhou, Lei Zhong, +5 authors, Jie Sun.
Sci Rep, 2016 Aug 10; 6. PMID: 27503456    Free PMC article.
Highly Cited.
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Sandra Casimiro, Arlindo R Ferreira, +2 authors, Luis Costa.
Int J Mol Sci, 2016 Sep 14; 17(9). PMID: 27618899    Free PMC article.
Review.
Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Vida Pourteimoor, Samira Mohammadi-Yeganeh, Mahdi Paryan.
Tumour Biol, 2016 Sep 22; 37(11). PMID: 27651157
Review.
Future Prospects in Breast Cancer Research - Cancer Stem Cells.
Floor Wolbers, Henk R Franke, +3 authors, István Vermes.
EJIFCC, 2012 Oct 01; 23(3). PMID: 27683420    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
Kenneth M K Mark, Frederick S Varn, +2 authors, Chao Cheng.
BMC Cancer, 2017 May 04; 17(1). PMID: 28464832    Free PMC article.
Prognostic cancer gene signatures share common regulatory motifs.
Ying Wang, Steve Goodison, Xiaoman Li, Haiyan Hu.
Sci Rep, 2017 Jul 08; 7(1). PMID: 28684851    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Ian Krop, Nofisat Ismaila, +10 authors, Vered Stearns.
J Clin Oncol, 2017 Jul 12; 35(24). PMID: 28692382    Free PMC article.
Highly Cited.
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.
Holly Janes, Marshall D Brown, +2 authors, William E Barlow.
Contemp Clin Trials, 2017 Aug 19; 63. PMID: 28818434    Free PMC article.
MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
Andreas Bösl, Andreas Spitzmüller, +3 authors, Felix Offner.
PLoS One, 2017 Aug 30; 12(8). PMID: 28850621    Free PMC article.
How Do Patients Experience Individualized Medicine? A Qualitative Interview-based Study of Gene Expression Analyses in the Treatment of Breast Cancer.
Sebastian Schleidgen, Sandra Thiersch, Rachel Wuerstlein, Georg Marckmann.
Geburtshilfe Frauenheilkd, 2017 Sep 30; 77(9). PMID: 28959062    Free PMC article.
Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.
E Nilüfer Güler.
Eur J Breast Health, 2017 Oct 31; 13(4). PMID: 29082373    Free PMC article.
Review.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Review.
Molecular Signatures of Radiation Response in Breast Cancer: Towards Personalized Decision-Making in Radiation Treatment.
Corey Speers, Lori J Pierce.
Int J Breast Cancer, 2018 Jan 20; 2017. PMID: 29348942    Free PMC article.
Review.
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Niaz Mahmood, Catalin Mihalcioiu, Shafaat A Rabbani.
Front Oncol, 2018 Feb 28; 8. PMID: 29484286    Free PMC article.
Highly Cited. Review.
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
S Aggarwal, A Vaid, +10 authors, D Doval.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721472    Free PMC article.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review.
David Krug, René Baumann, +12 authors, Rolf Sauer.
Breast Care (Basel), 2020 May 14; 15(2). PMID: 32398980    Free PMC article.
Review.
Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
Aurelia Noske, Sophie-Isabelle Anders, +6 authors, Evelyn Klein.
Breast, 2019 Dec 02; 49. PMID: 31786414    Free PMC article.
Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Yanding Zhao, Evelien Schaafsma, Chao Cheng.
Cancer Med, 2020 Jul 22; 9(17). PMID: 32692484    Free PMC article.
Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.
Ishita Gupta, Rasha M Sareyeldin, +4 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2019 Mar 16; 11(3). PMID: 30871273    Free PMC article.
Review.
Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis.
Xiaoying Zhou, Chuanguang Xiao, +6 authors, Lili Lin.
World J Surg Oncol, 2020 Sep 27; 18(1). PMID: 32977823    Free PMC article.
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Paolo Giorgi Rossi, Annette Lebeau, +13 authors, ECIBC Contributor Group.
Br J Cancer, 2021 Feb 19; 124(9). PMID: 33597715
Review.
Recent advances in neoadjuvant therapy for breast cancer.
David A Potter, César A Herrera-Ponzanelli, +5 authors, Douglas Yee.
Fac Rev, 2021 Mar 05; 10. PMID: 33659921    Free PMC article.
Review.